Allakos Inc. announced that it has successfully completed dosing in the Phase 1 clinical trial of AK001 in healthy volunteers and subjects with atopic disease. AK001 is a therapeutic antibody intended for the treatment of severe allergic diseases and diseases characterized by excess activity of mast cells and eosinophils. The randomized, double-blind, placebo-controlled, single-ascending-dose study enrolled 34 subjects to evaluate the safety, tolerability and pharmacokinetics of AK001 in a range of potentially active doses and to obtain early signals of pharmacodynamic activity.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8235 USD | -1.91% | -0.78% | -69.84% |
01/07 | Allakos Inc.(NasdaqGS:ALLK) dropped from Russell 3000E Value Index | CI |
01/07 | Allakos Inc.(NasdaqGS:ALLK) dropped from Russell 2000 Value Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-69.84% | 72.92M | |
+20.03% | 126B | |
+23.61% | 117B | |
+22.68% | 27.52B | |
-18.07% | 20.87B | |
-13.97% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B |
- Stock Market
- Equities
- ALLK Stock
- News Allakos Inc.
- Allakos Successfully Completes Dosing in Phase 1 Clinical Trial of AK001